Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Tjoung-Won Park-Simon, Gordon Rustin, Florence Joly, Mansoor Raza Mirza, Marie Plante, Michael S Quinn, Andrés Poveda, Gordon C Jayson, Dan Stark, Ann Marie SwartLaura Farrelly, Richard Kaplan, Mahesh K B Parmar, Timothy J Perren, ICON7 trial investigators

Research output: Contribution to journalJournal articleResearchpeer-review

338 Citations (Scopus)
188 Downloads (Pure)
Original languageEnglish
JournalLancet Oncology
Volume16
Issue number8
Pages (from-to)928-936
Number of pages9
ISSN1470-2045
DOIs
Publication statusPublished - Aug 2015

Bibliographical note

Member of NSGO Group

Keywords

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols
  • Australia
  • Bevacizumab
  • Canada
  • Carboplatin
  • Disease Progression
  • Disease-Free Survival
  • Drug Administration Schedule
  • Europe
  • Female
  • Humans
  • Infusions, Intravenous
  • Intention to Treat Analysis
  • Neoplasm Grading
  • Neoplasm Staging
  • New Zealand
  • Ovarian Neoplasms
  • Paclitaxel
  • Survival Analysis
  • Time Factors
  • Treatment Outcome
  • Clinical Trial, Phase III
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial'. Together they form a unique fingerprint.

Cite this